Study highlights calcium-to-magnesium ratio as a superior biomarker for nephrolithiasis in primary hyperparathyroidism.

If approved, it would be the first targeted PET imaging agent for kidney cancer available in the U.S., highlighting Telix’s expanding presence in the urology imaging market. Investors might find ...

Here’s what they found. Imaging Patterns in ADPKD and the Problem With Kidney Stones Patients with autosomal dominant polycystic kidney disease have more kidney stones than the general ...

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®. Telix Pharmaceuticals has submitted a Biologics License ...